Board summary
Key figures
55,338
Registered population
59.1% aged 18–64
18.6%
Aged 65+
ICB 20.0% · England 17.9%
21.8%
Ethnic minority (non-White)
18.9% Asian · England 9.6%
51.1%
In IMD quintile 1
ICB 30.6% · England 21.0%
~25,421
Core20 residents (est.)
Resident basis; registered basis ~29,060 · see page 3
9,056
Hypertension register
+6.10% in 3 yrs · England +5.60%
577
SMI register
47.7% of Burnley's
1,488
COPD register
Reviews +4.23% in 3 yrs
Forecast to 2030
10,484
Hypertension patients, 2030
+1,428 on today
67.9%
QRISK ≥20% on statins, 2030
+3.79pp over 3 yrs
4.5%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
High-risk lipid therapy trails national and local benchmarks.
Only 59.5% of patients with QRISK ≥ 20% receive lipid-lowering therapy, below Burnley (61.3%), the ICB (61.4%), and England (63.6%).
Pre-school MMR2 and 4-in-1 boosters fall short.
Age-5 MMR coverage drops 9.6 pp from dose 1 (94.3%) to dose 2 (84.7%), with 4-in-1 at 82.2% against the 95.0% target.
Hypertension, COPD, and SMI checks exceed England.
Hypertension treated to target reaches 73.2% (England 70.3%), alongside 83.4% COPD review coverage (England 76.4%) and 89.3% SMI BP checks (England 83.4%).
Population, age and ethnicity
Children comprise 22.3% and Asian residents 18.9%, with marked concentration across practices
Across six practices and 55,338 registered patients, 22.3% are aged 0-17 (Burnley 22.5%, ICB 19.6%, England 19.6%) and 18.6% are aged 65+ (Burnley 16.7%, ICB 20.0%, England 17.9%). Census usual-resident ethnicity shows an Asian / Asian British share of 18.9% (Burnley 14.7%, ICB 9.4%, England 9.6%), concentrated at Colne Road Surgery (49.9%) compared to Burnley Wood Medical Centre (5.2%). White residents represent 78.2% (Burnley 82.5%, ICB 87.8%, England 81.1%). Registered patient ethnicity may differ from resident Census bases.
Age profile
65+: ICB 20.0%, England 17.9%
Ethnicity
Older people · falls rows are Burnley local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Burnley LA) | 1,746 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.1% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.0% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Burnley LA) | 675 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Burnley LA) | 14.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 51.1% overall but spans 77.5 percentage points between practices
Across the PCN, 51.1% of registered patients live in Core20 areas, compared to Burnley (52.5%), NHS Lancashire and South Cumbria Integrated Care Board (30.6%), and England (21.0%). Across captured practices, the range is 77.5 pp. Briercliffe Surgery records 8.0%, while Colne Road Surgery records 85.4%. Parkside Surgery holds the largest volume at 7,941 estimated Core20 patients. Delivery requires dual targeting across practice concentration and absolute patient volume.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
577
SMI register
1.03% recorded prevalence
375
Learning disability register
0.67% recorded prevalence
32
Care homes, 957 beds
In the PCN catchment
9.9%
Provide unpaid care
Burnley, Census 2021
Recorded prevalence is 1.0% for severe mental illness (577 patients; England 1.0%) and 0.7% for learning disability (375 patients; England 0.6%). Catchment care homes total 32 with 957 beds. In wider system measures, Burnley recorded 6 people sleeping rough in autumn 2025 (a borough snapshot), alongside a PCN ceiling estimate of 5,478 unpaid carers.
Severe mental illness: physical health checks
Recorded SMI blood pressure checks reach 89.3% (England 83.4%) and BMI checks reach 88.3% (England 82.1%). Over three years, BMI checks rose +2.7 pp (England +5.1 pp).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
9,056
Hypertension register
+6.10%
Register growth, 3 yrs
Burnley +7.94% · England +5.60%
+3.30pp
BP control, under 80
≤140/90 · +2.48pp aged 80+
+1,428
More patients by 2030
Forecast 10,484 (18.28%)
Hypertension case-finding and control
Burnley East PCN records 9,056 patients on its hypertension register (16.2% prevalence), below Burnley (16.3%) and NHS Lancashire and South Cumbria Integrated Care Board (17.2%), but above England (15.2%). Practice prevalence ranges from 11.6% at Colne Road Surgery to 17.7% at Parkside Surgery. Treatment to target reaches 73.2%, exceeding England (70.3%). Recent blood pressure checks cover 92.2% (England 90.0%), with three-year growth at +2.6% (England +3.6%). An unverified projection estimates 10,484 cases by 2030, a projected change of 1,428. Recorded prevalence variation between practices may reflect local case-mix or case-finding practices, testable through audit.
Lipids and statins
Patients with QRISK ≥ 20% treated with lipid lowering therapy reach 59.5%, below England (63.6%), Burnley (61.3%), and NHS Lancashire and South Cumbria Integrated Care Board (61.4%). Prescribed items per 1,000 for lipid-regulating drugs (18+, 2026) stand at 2,504 (England 4,100). Lower therapy rates among high-risk patients could reflect recall gaps, testable via clinical audit.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 107,621 | £1.70 | £1.64 | £1.86 | £182,956 |
| Cardiovascular (all), 2025 | 154,271 | £3.37 | £3.38 | £3.33 | £519,893 |
In 2026, the PCN prescribed 107,621 items for lipid-regulating drugs at £1.70 per item (Burnley £1.58, NHS Lancashire and South Cumbria Integrated Care Board £1.64, England £1.86). Across these items, the PCN spent £17,219 less than at England's unit cost, and £6,457 more than at the ICB's unit cost. Unit cost differences do not reflect treatment quality or clinical efficiency.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+14.40%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−4.27%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 2.7% (1,488 patients; England 1.9%), with 83.4% reviewed in the last 12 months (England 76.4%). Asthma prevalence is 7.6% (3,952 patients; England 6.6%), falling 4.3% over three years (England +0.5%). Asthma review coverage is 74.8% (England 65.7%), leaving an estimated 998 patients without a recorded review. Asthma management items prescribed per 1000 5-19 population are 1,543 (England 1,488). Review gaps could reflect recall tracking differences, unverified locally.
Cancer register and children's immunisation
Cancer prevalence is 3.8% (2,119 patients; England 3.8%). In Q1 2025/26, MMR dose 1 coverage at age 5 reached 94.3% (England 91.7%), while MMR dose 2 was 84.7% (England 82.8%), a dose difference of 9.6 pp. The 4-in-1 pre-school booster reached 82.2%, below the 95.0% target by 12.8 pp across 157 children. Dose differences may reflect pre-school recall attrition, unverified locally.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
52.4%
Lancashire and South Cumbria ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,010
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Lancashire and South Cumbria ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 86.0% | 85.4% | 6% | 1,561 |
| Prostate | 42.4% | 53.2% | 11% | 1,404 |
| Lung | 31.1% | 33.8% | 15% | 1,374 |
| Bowel | 44.2% | 47.0% | 13% | 1,198 |
| Skin cancer | 86.1% | 87.8% | 21% | 519 |
In 2022, NHS Lancashire and South Cumbria ICB diagnosed 52.4% of cancers at stage 1 or 2 among known-stage cases (4,642 of 8,863), 22.6 pp below the 75.0% national ambition (England 55.3%). Known-stage completeness was 74.6% (8,863 of 11,883 cases; England 67.0%). Across the ICB, early-stage share fell 1.2 pp from 2013 to 2022, requiring about 2,010 extra early-stage cases annually to reach 75.0%. This describes the wider system, not PCN delivery. Locally, PCN cervical screening coverage (25-49 yrs) is 66.8%, with a 2023 to 2025 change of -2.6% (England -1.0%), reaching 47.8% at Colne Road Surgery. Lagging screening uptake risks delayed detection, testable via practice recall audit.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), East Lancashire Hospitals NHS Trust met the 28-day faster diagnosis standard at 81.5% (standard 75.0%; Northern Care Alliance NHS Foundation Trust 75.2%, Airedale NHS Foundation Trust 87.7%, ICB 78.4%, England 79.3%) and the 31-day standard at 98.1% (standard 96.0%; ICB 93.6%, England 92.5%). On the 62-day referral to treatment standard, it reached 73.2% against the 85.0% target (ICB 73.6%, England 71.2%). Diagnostic 6+ week waits were 0.4% for MRI and 0.1% for CT (England 21.4% and 9.9%). Provider data reflects wider system capacity, not PCN performance.
| Pathways within standard (%) | East Lancashire | Northern Care Alliance | Airedale | Lancashire and South Cumbria ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 81.50 | 75.20 | 87.71 | 78.39 | 79.32 |
| 31-day treatment (96%) | 98.11 | 94.54 | 98.20 | 93.62 | 92.50 |
| 62-day referral to treatment (85%) | 73.16 | 78.65 | 88.89 | 73.62 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Lancashire | Northern Care Alliance | Airedale | England |
|---|---|---|---|---|
| MRI | 0.43 | 5.09 | 2.91 | 21.40 |
| CT | 0.15 | 4.10 | 0.00 | 9.92 |
| Echocardiography | 0.00 | 31.48 | 0.70 | 28.48 |
| Colonoscopy | 0.95 | 40.04 | 31.21 | 30.83 |
| Gastroscopy | 1.16 | 36.48 | 22.98 | 29.02 |
| All 15 DM01 tests | 3.25 | 15.71 | 4.33 | 23.14 |
| Community services activity | Lancashire residents | Lancashire and South Cumbria ICB |
|---|---|---|
| Care contacts | 126,445 | 193,720 |
| Referrals | 20,415 | 29,855 |
| Patients with a contact | 47,320 | 65,335 |
Community services (residents of Lancashire), Jun 2026 (provisional). In June 2026 (provisional), community health service activity recorded 126,445 total contacts for borough residents. Contacts with adults aged 65 and over accounted for 56.9% of this activity (72,000 contacts), reflecting substantial older-adult demand within the wider community care system.
Practice variation and patient experience
Practice variation and patient experience
In 2025/26, practice overall QOF achievement ranged from 90.4% at Parkside Surgery to 98.2% at Yorkshire Street Medical Centre. Clinical domain achievement reached 98.1% at Briercliffe Surgery. Vaccination and immunisation achievement spanned 72.2 pp, from 15.6% at Parkside Surgery to 87.8% at Yorkshire Street Medical Centre (England 55.2%). Variation across practices was wider in vaccination and immunisation than overall clinical.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Parkside Surgery | 123 | 50.2 | 38.4% | 60.4% | 79.5% |
| Yorkshire Street | 106 | 57.8 | 81.4% | 58.0% | 79.4% |
| Burnley Wood | 106 | 61.4 | 63.1% | 65.1% | 73.9% |
| Briercliffe | 92 | 8.0 | 67.9% | 62.8% | 72.5% |
| Colne Road Surgery | 93 | 85.4 | 61.0% | 82.7% | 70.2% |
| Thursby Surgery | 92 | 55.5 | 42.1% | 85.1% | 68.8% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Twelve of 25 measures trail England's three-year change, while clinical reviews improved
Across 25 measures, 12 trail England's three-year change. Breast screening coverage increased +0.5% over 2023 to 2024 against England's +8.4% (trailing by 7.91 points), learning disability prevalence fell 2.3% (Burnley +5.1%, England +5.4%), and asthma prevalence fell 4.3% (England +0.5%). Conversely, non-frail diabetes HbA1c control improved +14.5% (England +4.4%) and asthma reviews rose +14.4% (England +4.4%). These diverging trends could reflect shifts in diagnostic coding or case-finding rather than changes in underlying need, unverified locally and testable through clinical coding audits.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Breast screening (53-70)
Learning disability register
Asthma register
Heart failure reviews
BMI record (SMI)
Diabetes HbA1c control
Asthma reviews
BP control, under 80
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Burnley | Asset | PCN | Burnley |
|---|---|---|---|---|---|
| Care homes (catchment) | 32 (957 beds) | n/a | Schools (catchment) | 97 | n/a |
| Children's centres | 5 | 6 | Places of worship | 46 | 54 |
| Libraries | 5 | 6 | Homelessness support (VCS) | 1 | 1 |
| Primary schools (LA maintained) | 22 | 26 | Primary academies | 6 | 6 |
| Special schools | 2 | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review and recall
Asthma review coverage is 74.8% (Burnley 67.8%, England 65.7%), leaving an estimated 998 of 3,952 asthma patients unreviewed, while three-year prevalence fell 4.3% (England +0.5%). For discussion: run a single-template asthma recall and register coding audit, pairing flexible review slots with inhaler checks. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
High-risk lipid and hypertension audit
QRISK ≥ 20% lipid therapy is 59.5% (Burnley 61.3%, ICB 61.4%, England 63.6%); hypertension prevalence is 16.2% (ICB 17.2%), from 11.6% at Colne Road Surgery to 17.7% at Parkside Surgery. For discussion: run a pharmacist-led recall of untreated QRISK ≥ 20% patients alongside opportunistic blood pressure checks. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Pre-school booster recall and alignment
In Q1 2025/26 (157 children), age-5 MMR2 is 84.7% vs 94.3% for MMR1 (9.6 pp difference) and 4-in-1 is 82.2%; QOF vaccination achievement spans 72.2 pp (15.6% to 87.8%). For discussion: audit age-5 children who had MMR1 without MMR2 or 4-in-1, aligning practice call-recall workflows. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Tailored language and communication outreach (p2) | Asian / Asian British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health recall review (p4) | Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Targeted hypertension case finding (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall outreach (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted cervical screening recall (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Structured asthma review and recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · High-risk lipid and hypertension audit (p12) | Patients with QRISK ≥ 20% treated with lipid lowering therapy · Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 3 · Pre-school booster recall and alignment (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
